538 related articles for article (PubMed ID: 26996617)
1. Review on EGFR Inhibitors: Critical Updates.
Singh D; Attri BK; Gill RK; Bariwal J
Mini Rev Med Chem; 2016; 16(14):1134-66. PubMed ID: 26996617
[TBL] [Abstract][Full Text] [Related]
2. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
4. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
[TBL] [Abstract][Full Text] [Related]
5. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
Sabbah DA; Hajjo R; Sweidan K
Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of selective degraders of EGFR
Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K
Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162
[TBL] [Abstract][Full Text] [Related]
7. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress.
Sharma B; Singh VJ; Chawla PA
Bioorg Chem; 2021 Nov; 116():105393. PubMed ID: 34628226
[TBL] [Abstract][Full Text] [Related]
9. Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds.
Yu-Jing YJ; Zhang CM; Liu ZP
Anticancer Agents Med Chem; 2012 May; 12(4):391-406. PubMed ID: 22043991
[TBL] [Abstract][Full Text] [Related]
10. Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy.
Cheng W; Zhou J; Tian X; Zhang X
Curr Med Chem; 2016; 23(29):3343-3359. PubMed ID: 27160532
[TBL] [Abstract][Full Text] [Related]
11. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
Cheng W; Hu Y; Sheng R
Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
[TBL] [Abstract][Full Text] [Related]
12. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
[TBL] [Abstract][Full Text] [Related]
14. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
15. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting two cellular mutant epidermal growth factor receptor tyrosine kinases by addressing computationally assessed crystal ligand pockets.
Lee JH; Lin WC; Wen TK; Wang C; Lin YT
Future Med Chem; 2019 Apr; 11(8):833-846. PubMed ID: 30724109
[No Abstract] [Full Text] [Related]
17. Identification and Pharmacological Analysis of High Efficacy Small Molecule Inhibitors of EGF-EGFR Interactions in Clinical Treatment of Non-Small Cell Lung Carcinoma: a Computational Approach.
Gudala S; Khan U; Kanungo N; Bandaru S; Hussain T; Parihar M; Nayarisseri A; Mundluru HP
Asian Pac J Cancer Prev; 2015; 16(18):8191-6. PubMed ID: 26745059
[TBL] [Abstract][Full Text] [Related]
18. Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors.
Yang RY; Yang KS; Pike LJ; Marshall GR
Chem Biol Drug Des; 2010 Jul; 76(1):1-9. PubMed ID: 20456371
[TBL] [Abstract][Full Text] [Related]
19. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
Song Z; Ge Y; Wang C; Huang S; Shu X; Liu K; Zhou Y; Ma X
J Med Chem; 2016 Jul; 59(14):6580-94. PubMed ID: 26882288
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
